Status:
COMPLETED
Cardiovascular Prevention for Persons With HIV
Lead Sponsor:
Hennepin Healthcare Research Institute
Collaborating Sponsors:
American Heart Association
Conditions:
HIV Infection
Cardiovascular Disease Risk
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection. Evidence suggests th...
Eligibility Criteria
Inclusion
- HIV Infection with viral load 'undetectable' while taking antiretroviral therapy
- Age ≥40
- Framingham risk score (FRS) ≥5%, or ≥3% with ≥5 years of exposure to antiretroviral therapy
Exclusion
- Known cardiovascular disease or Framingham risk score (FRS) ≥20%
- Blood pressure ≥140/90
- LDL cholesterol ≥160 (with FRS \<10%), or ≥130 (with FRS 10-20%)
- Currently taking, or has a medication contraindication to take, a 'statin', an ACE inhibitor, or an angiotensin receptor blocker medication
- Cirrhosis or plasma ALT/AST levels \>2x upper limit of normal
- Chronic kidney disease and a creatinine \>2.0mg/dL
- Triglycerides \>500mg/dL
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00982189
Start Date
September 1 2009
End Date
May 1 2011
Last Update
November 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415